Table 1 Demographic and clinicopathologic characteristics of 308 subjects comprising ELISA study cohort and 173 subjects comprising IHC study cohort
From: Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection
| Â | ELISA Cohort | IHC Cohort | ||
|---|---|---|---|---|
| Â | BCa (%) n = 102 | Controls (%) n = 206 | BCa (%) n = 165 | Controls (%) n = 8 |
Median Age (range, y) | 69 (20 – 93) | 56 (18 – 89) | 67 (47 – 91) | 59 (42 – 83) |
Male : Female ratio | 84 : 18 | 152 : 54 | 132 : 33 | 7 : 1 |
Race | Â | Â | Â | Â |
  White | 91 (90%) | 135 (66%) | 137 (83%) | 7 (88%) |
  African American | 5 (5.9%) | 20 (10%) | 8 (5%) | 0 (0%) |
  Other | 6 (6.1%) | 51 (24%) | 20 (12%) | 1 (12%) |
Positive FISH | 40 / 74 (54%) | 2/22(9%) | N/A | N/A |
Suspicious/positive cytology | 37 / 94 (39%) | 2/22(9%) | N/A | N/A |
Median follow-up (months) | 14 | 4 | 11 | 3 |
Clinical stage | Â | Â | Â | Â |
  Tis | 6 (6%) |  | 15 (9%) |  |
  Ta | 41 (40%) |  | 15 (9%) |  |
  T1 | 14 (14%) |  | 15 (9%) |  |
  ≥T2 | 41 (40%) |  | 120 (73%) |  |
Tumor grade | Â | Â | Â | Â |
  Low | 38 (37%) |  | 36 (22%) |  |
  High | 64 (63%) |  | 129 (78%) |  |
Median tumor size (cm) | 3.0 | Â | 3.5 | Â |
Median urinary CCL18 pg/ml (range) | 52.84 | 11.13 | Â | Â |
(2–6949) | (0–662) | |||
Median urinary A1AT ng/ml (range) | 606.4 | 120.0 | Â | Â |
(26–8830) | (1–1997) | |||
Median urinary protein μg/ml (range) | 24.2 | 38.9 |  |  |
|  | (24–789) | (24–561) |  |  |